- Home
- ZYME vs NRK Comparison
ZYME vs NRK Comparison
Compare ZYME & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- NRK
- Stock Information
- Founded
- ZYME 2003
- NRK 2002
- Country
- ZYME United States
- NRK United States
- Employees
- ZYME N/A
- NRK N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- ZYME Health Care
- NRK Finance
- Exchange
- ZYME Nasdaq
- NRK Nasdaq
- Market Cap
- ZYME 846.1M
- NRK 922.1M
- IPO Year
- ZYME 2017
- NRK N/A
- Fundamental
- Price
- ZYME $11.43
- NRK $9.83
- Analyst Decision
- ZYME Buy
- NRK
- Analyst Count
- ZYME 7
- NRK 0
- Target Price
- ZYME $19.50
- NRK N/A
- AVG Volume (30 Days)
- ZYME 449.0K
- NRK 187.3K
- Earning Date
- ZYME 05-08-2025
- NRK 01-01-0001
- Dividend Yield
- ZYME N/A
- NRK 4.10%
- EPS Growth
- ZYME N/A
- NRK N/A
- EPS
- ZYME N/A
- NRK N/A
- Revenue
- ZYME $93,384,000.00
- NRK N/A
- Revenue This Year
- ZYME $34.23
- NRK N/A
- Revenue Next Year
- ZYME $68.78
- NRK N/A
- P/E Ratio
- ZYME N/A
- NRK N/A
- Revenue Growth
- ZYME 85.05
- NRK N/A
- 52 Week Low
- ZYME $8.21
- NRK $8.95
- 52 Week High
- ZYME $17.70
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- ZYME 45.92
- NRK 41.09
- Support Level
- ZYME $11.46
- NRK $9.75
- Resistance Level
- ZYME $11.81
- NRK $9.85
- Average True Range (ATR)
- ZYME 0.59
- NRK 0.08
- MACD
- ZYME -0.05
- NRK -0.01
- Stochastic Oscillator
- ZYME 27.62
- NRK 27.63
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.